V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 210033655 | 210013676 | 1.7 | null | Disease modification (D) | 2019-06-24 | 2019-06-29 | Lenalidomide Cycle 26 onwards (PAS) | Y | N | 210001193 | CHLVPP |
| 210033656 | 210022543 | 1.75 | 91.65 | Palliative (P) | 2019-08-10 | 2019-08-18 | CVP | N | N | 210004103 | PEMBROLIZUMAB |
| 210033657 | 210013688 | 1.82 | 0 | Curative (C) | null | 2018-02-13 | AML 19 TRIAL | 01 | N | 210008796 | CISPLATIN + VINORELBINE |
| 210033658 | 210013691 | 1.68 | 60.6 | Palliative (P) | 2016-08-30 | 2017-11-02 | Mitomycin Intravesical | N | N | 210010386 | ALL |
| 210033659 | 210022554 | null | 64.1 | Palliative (P) | 2017-11-03 | 2017-11-03 | Cytarabine intrathecal | Y | N | 210011848 | PIXANTRONE |
| 210033660 | 210022555 | 1.7 | 83 | Palliative (P) | 2019-03-27 | 2019-03-27 | LENALIDOMIDE + dexamethasone | N | N | 210012655 | CLL210 TRIAL |
| 210033661 | 210013709 | null | 72 | Palliative (P) | 2018-08-15 | 2018-08-15 | CAV | N | N | 210021324 | R-EPOCH |
| 210033662 | 210013714 | 1.54 | 61.7 | Curative (C) | 2018-02-26 | 2018-02-26 | PNET 4 HIT-SIOP Maintenance | 02 | N | 210021743 | ALL |
| 210033663 | 210013718 | 1.46 | 94.9 | Palliative (P) | 2017-06-05 | 2017-07-31 | CARBOPLATIN + PACLITAXEL | N | N | 210021911 | OFATUMUMAB |
| 210033664 | 210013721 | null | null | Palliative (P) | null | 2016-08-04 | Lenalidomide 25mg (Cycle 1 to 25) | Y | N | 210022095 | PENTOSTATIN + RITUXIMAB |
| 210033665 | 210013731 | 1.82 | 77.7 | Palliative (P) | 2017-09-05 | 2017-09-06 | Fludarabine IV | N | N | 210023716 | CYCLOPHOSPHAMIDE + LENALIDOMIDE |
| 210033666 | 210022581 | 1.76 | 99.7 | Disease modification (D) | 2015-10-21 | 2015-11-29 | DOXORUBICIN | N | N | 210024647 | CYTARABINE INTRATHECAL |
| 210033667 | 210013745 | 0 | 78 | Curative (C) | 2019-09-23 | 2019-09-23 | Mini BEAM | N | Y | 210024837 | CYTARABINE HD + METHOTREXATE HD |
| 210033668 | 210022585 | null | 117.5 | Curative (C) | 2017-11-08 | 2017-11-08 | BR14 TRIAL | 2 | N | 210025077 | CISPLATIN + GEMCITABINE + RITUXIMAB |
| 210033669 | 210013751 | 1.86 | 98 | Curative (C) | 2016-11-09 | 2016-11-09 | PACLITAXEL | Y | N | 210025389 | UKALL 60+ TRIAL |
| 210033670 | 210013759 | 1.56 | null | null | 2017-01-08 | 2017-01-08 | DOXORUBICIN | null | N | 210025962 | DA |
| 210033671 | 210013761 | 1.85 | null | Curative (C) | 2018-04-04 | 2018-08-23 | Cytarabine intrathecal | 02 | N | 210026674 | BORTEZOMIB |
| 210033672 | 210013770 | 0 | 60.4 | Curative (C) | 2014-09-21 | 2014-10-25 | Vinorelbine IV | N | N | 210027566 | ABVD |
| 210033673 | 210013774 | 1.88 | null | Curative (C) | 2019-04-04 | 2019-04-04 | ALEMTUZUMAB + BUSULFAN + FLUDARABINE | Y | N | 210027899 | ALEMTUZUMAB + CYCLOPHOSPHAMIDE |
| 210033674 | 210013781 | 1.75 | 88 | Curative (C) | 2019-07-05 | 2019-07-05 | CISPLATIN + VINORELBINE + RT | N | null | 210028000 | DAUNORUBICIN |
| 210033675 | 210013782 | 1.67 | 90.95 | null | 2015-09-06 | 2015-09-06 | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | null | N | 210028065 | AML19 TRIAL |
| 210033676 | 210013785 | 1.46 | 65.3 | Palliative (P) | 2018-03-19 | 2018-03-22 | Carboplatin + Paclitaxel (weekly) | Y | N | 210028634 | CYTARABINE HD + METHOTREXATE HD |
| 210033677 | 210013796 | 1.87 | 81.8 | Curative (C) | 2018-04-17 | 2018-04-21 | Bevacizumab + LOMUSTINE | 2 | N | 210029239 | R CODOX M |
| 210033678 | 210013800 | 1.72 | 63.3 | Curative (C) | 2019-03-16 | 2019-04-06 | Packer Maintenance Regimen | N | null | 210029407 | CYTARABINE HD + METHOTREXATE HD |
| 210033679 | 210013803 | 1.7 | 63 | Palliative (P) | 2016-09-14 | 2016-09-18 | Ofatumumab Loading | Y | N | 210029552 | ALEMTUZUMAB + CYCLO + FLUDARABINE |
| 210033680 | 210013807 | 1.67 | 76.6 | Curative (C) | 2015-11-02 | 2015-11-03 | Capecitabine (21days) + Carboplatin | N | null | 210029666 | R CODOX M |
| 210033681 | 210022624 | 1.68 | 44.9 | Curative (C) | 2019-02-05 | 2019-02-08 | ABVD | 2 | N | 210030225 | DACTINOMYCIN + VINCRISTINE |
| 210033682 | 210028195 | 1.82 | 76.8 | Curative (C) | 2018-07-19 | 2018-07-19 | BR14 TRIAL | N | Y | 210030276 | CLL210 TRIAL |
| 210033683 | 210028196 | null | 16.5 | Curative (C) | 2018-05-02 | 2018-09-15 | PENTOSTATIN + RITUXIMAB | N | null | 210030490 | NHL 2003 |
| 210033684 | 210013818 | 1.72 | 89 | Curative (C) | 2018-06-03 | 2018-11-27 | DACTINOMYCIN + CYCLO + VINCRISTINE | 02 | N | 210030551 | CARFILZOMIB |
| 210033685 | 210013826 | null | null | Curative (C) | 2016-05-04 | 2016-05-04 | Nilotinib | N | null | 210030851 | CVD |
| 210033686 | 210013835 | 1.52 | null | Neo-adjuvant (N) | 2017-01-18 | 2017-01-18 | BR14 TRIAL | 02 | N | 210031093 | CARBO + ETOPOSIDE + VINCRISTINE |
| 210033687 | 210013840 | 1.73 | 66.2 | Palliative (P) | 2017-07-30 | 2017-07-30 | PIXANTRONE | N | N | 210031205 | TAMIGA TRIAL |
| 210033688 | 210013844 | 1.85 | 18.1 | Curative (C) | 2019-01-23 | 2019-01-26 | RUXOLITINIB | N | Y | 210031222 | CYCLO + FLUDARABINE + RITUXIMAB |
| 210033689 | 210022642 | 1.7 | 112.8 | Curative (C) | 2018-04-21 | 2018-04-28 | FCR IV - Cycle 2 onwards | Y | N | 210031422 | CYCLOPHOSPHAMIDE + ETOPOSIDE + NELARABINE |
| 210033690 | 210013846 | 1.5 | 82.3 | null | 2019-06-16 | 2019-09-14 | PACLITAXEL | N | N | 210031442 | ALL |
| 210033691 | 210013850 | 1.9 | 87.6 | Curative (C) | 2016-11-27 | 2016-12-25 | Packer Maintenance Regimen | Y | N | 210031639 | ALL |
| 210033692 | 210022653 | 0 | 68.8 | Curative (C) | 2018-02-23 | 2018-03-04 | CYCLET | N | N | 210032185 | ALL MAINTENANCE |
| 210033693 | 210028214 | 1.66 | 35.5 | Curative (C) | null | 2018-02-27 | Capecitabine (21days) + Carboplatin | N | N | 210032710 | DABRAFENIB + TRAMETINIB |
| 210033694 | 210013877 | null | 10.8 | Palliative (P) | 2018-04-13 | 2018-04-15 | CLL210 TRIAL | N | N | 210032994 | BEVACIZUMAB + IRINOTECAN |
| 210033695 | 210028217 | 1.73 | 30.2 | Palliative (P) | 2019-01-01 | 2019-01-01 | Cytarabine intrathecal | 02 | N | 210033021 | CYCLOPHOSPHAMIDE HIGH DOSE |
| 210033696 | 210013880 | null | 8.8 | Curative (C) | 2017-10-26 | 2017-11-01 | CYCLOPHOSPHAMIDE + ETOPOSIDE + NELARABINE | 02 | N | 210033199 | VINORELBINE |
| 210033697 | 210022665 | 1.85 | 0 | Curative (C) | 2017-10-07 | 2019-02-28 | VEDex | N | N | 210033602 | DOCETAXEL |
| 210033698 | 210013891 | 1.74 | 59.45 | Disease modification (D) | null | 2019-06-22 | CLARITY Trial | 2 | N | 210033677 | NHL 2003 |
| 210033699 | 210013895 | 1.63 | 84 | Palliative (P) | 2017-11-14 | 2017-12-05 | CYCLET | 1 | N | 210033710 | CYTARABINE |
| 210033700 | 210013899 | null | 13.3 | Adjuvant (A) | 2018-11-29 | 2019-01-09 | LOMUSTINE + VINCRISTINE | N | N | 210033837 | IVAC |
| 210033701 | 210013903 | 1.56 | 79.75 | Not known (9) | 2019-02-17 | 2019-03-10 | Azacitidine | 99 | Y | 210033864 | BEAM |
| 210033702 | 210022678 | null | 46.3 | null | 2020-04-07 | 2020-04-07 | VINORELBINE | null | null | 210034315 | UKALL2003 |
| 210033703 | 210013915 | 1.65 | 6.25 | Palliative (P) | 2016-05-09 | 2016-05-25 | ALL Int Guide B Int Maint Ph III | N | N | 210034385 | FLUDARABINE + MELPHALAN |
| 210033704 | 210022683 | 1.82 | null | Curative (C) | 2019-06-01 | 2019-06-30 | Capecitabine + Oxaliplatin 21day | 2 | N | 210034391 | DOCETAXEL |